Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Net Income (2016 - 2024)

Mimedx (MDXG) has disclosed Net Income for 14 consecutive years, with $217000.0 as the latest value for Q3 2024.

  • Quarterly Net Income rose 170.45% to $217000.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $217000.0 through Jun 2025, down 89.59% year-over-year, with the annual reading at $421000.0 for FY2024, 104.57% up from the prior year.
  • Net Income hit $217000.0 in Q3 2024 for Mimedx, up from $4000.0 in the prior quarter.
  • In the past five years, Net Income ranged from a high of $9.8 million in Q4 2022 to a low of -$19.4 million in Q3 2020.
  • Historically, Net Income has averaged -$4.8 million across 5 years, with a median of -$3.0 million in 2023.
  • Biggest YoY gain for Net Income was 4839.7% in 2022; the steepest drop was 510.91% in 2022.
  • Year by year, Net Income stood at -$16.6 million in 2020, then skyrocketed by 101.2% to $199000.0 in 2021, then surged by 4839.7% to $9.8 million in 2022, then crashed by 77.73% to $2.2 million in 2023, then tumbled by 90.09% to $217000.0 in 2024.
  • Business Quant data shows Net Income for MDXG at $217000.0 in Q3 2024, $4000.0 in Q2 2024, and $200000.0 in Q1 2024.